InsiderTradr

ValiRx plc (VAL.L)

LSE · GBp · Healthcare · Biotechnology

£0.135 (+0.00%) as of

Key statistics

Market cap
1.78M
Forward P/E
-0.00
EPS (TTM)
-0.0000
Dividend yield
0.00%
52-week range
0.1200 – 0.5000
Beta
-0.24
Revenue (TTM)
32.67k
Profit margin
0.00%
Volume
5.08M

About ValiRx plc

ValiRx plc, together with its subsidiaries, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL401, a reformulation of anti-psychotic drug risperidone, which completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer; VAL201, a short peptide, which completed Phase I/II clinical trial for the treatment of prostate cancer; and VAL301, a peptide, which is in pre-clinical trial for the treatment of endometriosis. It is also involved in the development of BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment of SARS-CoV2 infection; and CLX001, a peptide in a nanoparticle formulation for the treatment of triple negative breast cancer. The company was founded in 2006 and is based in London, the United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Headquarters
London, United Kingdom
Employees
11

valirx.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks